Invesco DB Oil Fund vs State Street SPDR S&P Biotech ETF — how do they compare? Invesco DB Oil Fund trades at $20.11, while State Street SPDR S&P Biotech ETF trades at $155.48. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals.
| DBO | XBI | |
|---|---|---|
Sector | Commodities - Energy | Broad Market / Factor |
52-Week High | $23.80 | $164.28 |
52-Week Low | $11.98 | $85.16 |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Trailing returns across standard periods
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →